Gastrointestinal Cancer News

LONDON — Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the main contributors of increased mortality related to chronic liver disease and liver cancer burden, according to research.

LONDON — Alcohol misuse was a primary trigger for progression of liver disease to hepatocellular carcinoma among a subset of French patients with type 2 diabetes, according to data presented at the International Liver Congress.

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

The FDA granted accelerated approval to dabrafenib plus trametinib for treatment of certain patients with unresectable or metastatic solid tumors that harbor BRAF V600E mutations.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 2 study presented at ASCO Annual Meeting on single-agent dostarlimab for patients with mismatch repair-deficient or microsatellite instability high rectal cancer.

Vaccinated patients with cancer had significantly higher risks for breakthrough COVID-19 infection, especially those undergoing active cancer care, compared with individuals without cancer, according to a study published in JAMA Oncology.

The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 3 PARADIGM trial presented at an ASCO Annual Meeting plenary session.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.